As the year winds down, STAT reporters are taking a look at the stories they’re most eager to track in 2018. Find all our “three to watch” series here


t’s been a busy year for the Food and Drug Administration — since Commissioner Scott Gottlieb was confirmed in May, he has led the agency with an ambitious agenda, tackling everything from prescription opioid addiction to tobacco use to dubious stem cell clinics.

And 2018 shows no signs of letting up. Many of the proclamations the FDA has made under Gottlieb will come to fruition, or at least to bud, in the new year.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.